Therapeutic vaccines for cancer: An overview of clinical trials

Nature Reviews Clinical Oncology

Volumn 11, Issue 9, 2014, Pages 509-524

  Melero, Ignacio ^a   Gaudernack, Gustav ^b   Gerritsen, Winald ^c   Huber, Christoph ^d   Parmiani, Giorgio ^e   Scholl, Suzy ^f   Thatcher, Nicholas ^g   Wagstaff, John ^h   Zielinski, Christoph ⁱ   Faulkner, Ian ^j   Mellstedt, Håkan ^k  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF OSLO   (Norway)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f INSTITUT CURIE   (France)

^g CHRISTIE HOSPITAL   (United Kingdom)

^h SINGLETON HOSPITAL   (United Kingdom)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j International Medical Press   (United Kingdom)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALGENPANTUCEL L; ANTINEOPLASTIC AGENT; BCG VACCINE; BELAGENPUMATUCEL L; CANCER VACCINE; CIMAVAX; CYCLOPHOSPHAMIDE; DACARBAZINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; GSK 2132231A; INTERLEUKIN 2; IPILIMUMAB; KEYHOLE LIMPET HEMOCYANIN; MELANOMA ANTIGEN 3; MUCIN 1; NELIPEPIMUT S; NEU VAX; PLACEBO; POXVIRUS VECTOR; PROSTATE SPECIFIC ANTIGEN; RACOTUMOMAB; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; TECEMOTIDE; TERGENPUMATUCEL L; TERTOMOTIDE; TG 4010; TRASTUZUMAB; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZASTUMOTIDE;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; BONE MARROW CELL; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHEMORADIOTHERAPY; CLINICAL PRACTICE; COLORECTAL CANCER; DENDRITIC CELL; DRUG EFFICACY; HEMATOLOGIC MALIGNANCY; HORMONAL THERAPY; HUMAN; HUMAN ADENOVIRUS 5; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; METASTATIC MELANOMA; MINOR HISTOCOMPATIBILITY COMPLEX; MULTIMODAL CHEMOTHERAPY; MULTIMODALITY CANCER THERAPY; MYELOID DERIVED SUPPRESSOR CELL; NEOPLASM; NONHUMAN; PANCREAS CANCER; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SINGLE DRUG DOSE; SUPPRESSOR CELL; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY, ACTIVE; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MELANOMA; NEOPLASMS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS;

EID: 85047692172     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.111     Document Type: Review

References (201)

1. Palena, C., Abrams, S. I., Schlom, J. & Hodge, J. W. Cancer vaccines: Preclinical studies and novel strategies. Adv. Cancer Res. 95, 115-145 (2006
2. Ogi, C. & Aruga, A. Immunological monitoring of anticancer vaccines in clinical trials. Oncoimmunology 2, e26012 (2013
3. Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480-489 (2011
4. Vesely, M. D. & Schreiber, R. D. Cancer immunoediting: Antigens, mechanisms, and implications to cancer immunotherapy. Ann. NY Acad. Sci. 1284, 1-5 (2013
5. Slingluff, C. L. Jr. The present and future of peptide vaccines for cancer: Single or multiple, long or short, alone or in combination? Cancer J. 17, 343-350 (2011
6. Zhang, X. M. et al. The anti-tumor immune response induced by a combination of MAGE 3/MAGE n derived peptides. Oncol. Rep. 20, 245-252 (2008
7. Disis, M. L. et al. Generation of T cell immunity to the HER 2/neu protein after active immunization with HER 2/neu peptide-based vaccines. J. Clin. Oncol. 20, 2624-2632 (2002
8. Butterfield, L. H. et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res. 9, 998-1008 (2003
9. Zeng, G. et al. Generation of NY ESO 1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: A new strategy for vaccine design. Cancer Res. 62, 3630-3635 (2002
10. Vermeij, R. et al. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study. Int. J. Cancer 131, E670-E680 (2012
11. Feyerabend, S. et al. Novel multi-peptide vaccination in Hla A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 69, 917-927 (2009
12. Walter, S. et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18, 1254-1261 (2012
13. Hickman, H. D. & Yewdell, J. W. Mining the plasma immunopeptidome for cancer peptides as biomarkers and beyond. Proc. Natl Acad. Sci. USA 107, 18747-18748 (2010
14. Castle, J. C. et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081-1091 (2012
15. Grun, J. L. & Maurer, P. H. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: The role of endogenous interleukin 1 in proliferative responses. Cell Immunol. 121, 134-145 (1989
16. Hailemichael, Y. et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat. Med. 19, 465-472 (2013
17. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010
18. Sandoval, F. et al. Mucosal imprinting of vaccine-induced CD8(+) T cells is crucial to inhibit the growth of mucosal tumors. Sci. Transl. Med. 5, 172ra20 (2013
19. Jongbloed, S. L. et al. Human CD141+ (BDCA 3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 207, 1247-1260 (2010
20. Bedoui, S. et al. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat. Immunol. 10, 488-495 (2009
21. Tel, J. et al. Tumoricidal activity of human dendritic cells. Trends Immunol. 35, 38-46 (2013
22. Hallermalm, K. et al. Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer. Scand. J. Immunol. 66, 43-51 (2007
23. Ishizaki, H. et al. Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression. J. Immunother. 33, 609-617 (2010
24. Naslund, T. I. et al. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. J. Immunol. 178, 6761-6769 (2007
25. Parmiani, G. et al. Opposite immune functions of GM CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol. 18, 226-232 (2007
26. Ranges, G. E., Figari, I. S., Espevik, T. & Palladino, M. A. Jr. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J. Exp. Med. 166, 991-998 (1987
27. Thomas, D. A. & Massague, J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369-380 (2005
28. Walker, M. R. et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+. J. Clin. Invest. 112, 1437-1443 (2003
29. Ghiringhelli, F. et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56, 641-648 (2007
30. Cerullo, V. et al. Immunological effects of low dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol. Ther. 19, 1737-1746 (2011
31. Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949 (2004
32. Kobayashi, N. et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin. Cancer Res. 13, 902-911 (2007
33. Whiteside, T. L. What are regulatory T cells (Treg) regulating in cancer and why? Semin. Cancer Biol. 22, 327-334 (2012
34. Correale, P. et al. Regulatory (FoxP3+) T cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J. Immunother. 33, 435-441 (2010
35. Schwartzentruber, D. J. et al. Gp100 peptide vaccine and interleukin 2 in patients with advanced melanoma. N. Engl. J. Med. 364, 2119-2127 (2011
36. Bergmann, C. et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: Mechanisms of suppression and expansion in advanced disease. Clin. Cancer Res. 14, 3706-3715 (2008
37. Iclozan, C., Antonia, S., Chiappori, A., Chen, D. T. & Gabrilovich, D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol. Immunother. 62, 909-918 (2013
38. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012
39. Blackburn, S. D. et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10, 29-37 (2009
40. Blank, C. et al. PD L1/B7H 1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 64, 1140-1145 (2004
41. Okazaki, T. & Honjo, T. PD 1 and PD 1 ligands: From discovery to clinical application. Int. Immunol. 19, 813-824 (2007
42. Brahmer, J. R. et al. Safety and activity of anti PD L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012
43. Topalian, S. L. et al. Safety, activity, and immune correlates of anti PD 1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012
44. Simpson, T. R. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti CTLA 4 therapy against melanoma. J. Exp. Med. 210, 1695-1710 (2013
45. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011
46. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti PD 1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013
47. Brahmer, J. R. et al. Survival and long-term follow-up of the phase I trial of nivolumab (anti PD 1; BMS 936558; ONO 4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 31 (Suppl.), a8030 (2013
48. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013
49. Burch, P. A. et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 6, 2175-2182 (2000
50. Kantoff, P. W. et al. Sipuleucel T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010
51. Galluzzi, L. et al. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 1, 1111-1134 (2012
52. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00065442 (2014
53. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00005947 (2014
54. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00779402 (2014).
55. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01133704 (2014
56. Kantoff, P. W. et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 1099-1105 (2010
57. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01322490 (2014
58. Geary, S. M. & Salem, A. K. Prostate cancer vaccines: Update on clinical development. Oncoimmunology 2, e24523 (2013
59. Lubaroff, D. M. et al. An ongoing Phase II trial of an adenovirus/PSA vaccine for prostate cancer [abstract]. Cancer Res. 72 (Suppl. 1), a2692 (2012
60. McNeel, D. G. et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J. Clin. Oncol. 27, 4047-4054 (2009
61. Becker, J. T. et al. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T cell responses in patients with recurrent prostate cancer. J. Immunother. 33, 639-647 (2010
62. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01706458 (2014
63. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00849121 (2014
64. Kübler, H. et al. Final analysis of a phase I/IIa study with CV9103, and intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA [abstract]. J. Clin. Oncol. 29 (Suppl.) a4535 (2011
65. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00831467 (2014
66. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01817738 (2014
67. Higano, C. S. et al. Phase 1/2 dose-escalation study of a GM CSF secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113, 975-984 (2008
68. Small, E. J. et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 13, 3883-3891 (2007
69. van Den Eertwegh, A. J. et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial. Lancet Oncol. 13, 509-517 (2012
70. Higano, C. et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) [abstract]. Presented at the Genitourinary Cancers Symposium, LBA150 (2009
71. Small, E. et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) [abstract]. Genitourinary Cancers Symposium, a07 (2009
72. Mittendorf, E. A. et al. Clinical trial results of the HER 2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: From US Military Cancer Institute Clinical Trials Group Study I 01 and I 02. Cancer 118, 2594-2602 (2012
73. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01479244 (2014
74. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01570036 (2014
75. Oka, Y. et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA 101, 13885-13890 (2004
76. Miles, D. et al. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 16, 1092-1100 (2011
77. Ibrahim, N. K. et al. Survival advantage in patients with metastatic breast cancer receiving endocrine therapy plus sialyl tn-klh vaccine: Post hoc analysis of a large randomized trial. J. Cancer 4, 577-584 (2013
78. Scholl, S. et al. Metastatic breast tumour regression following treatment by a gene-modified vaccinia virus expressing MUC1 and IL 2. J. Biomed. Biotechnol. 2003, 194-201 (2003
79. Butts, C. et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non small cell lung cancer (START): A randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 59-68 (2014
80. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01015443 (2014
81. Wu, Y. L. et al. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer 11, 430 (2011
82. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT02049151 (2014
83. Quoix, E. et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non small cell lung cancer: A controlled phase 2B trial. Lancet Oncol. 12, 1125-1133 (2011
84. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01383148 (2014
85. Vansteenkiste, J. et al. Adjuvant MAGE A3 immunotherapy in resected non small cell lung cancer: Phase II randomized study results. J. Clin. Oncol. 31, 2396-2403 (2013
86. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00480025 (2014
87. Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer. GlaxoSmithKline [online], http://www.gsk.com/media/press-releases/2014/update- on-phase-III-clinical-trial-of-investigational-MAGE-A3-antigen-specific-cancer- immunotherapeutic-in-non-small-cell-lung-cancer.html (2014
88. Brunsvig, P. F. et al. Telomerase peptide vaccination in NSCLC: A phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8 year update on a phase I/II trial. Clin. Cancer Res. 17, 6847-6857 (2011
89. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01579188 (2014
90. Neninger Vinageras, E. et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non small cell lung cancer. J. Clin. Oncol. 26, 1452-1458 (2008
91. Nemunaitis, J. et al. Phase II study of belagenpumatucel L, a transforming growth factor beta 2 antisense gene-modified allogeneic tumor cell vaccine in non small cell lung cancer. J. Clin. Oncol. 24, 4721-4730 (2006
92. Fakhrai, H., Tong, A., Nemunaitis, J. & Shawler, D. L. Correlation of immune responses and survival in a phase II study of belagenpumatucel L in non-small cell lung cancer [abstract]. J. Clin. Oncol. 15 (Suppl.), a3013 (2009
93. Giaccone, G. et al. A phase III study of belagenpumatucel L therapeutic tumor cell vaccine for non-small cell lung cancer (NSCLC) [abstract]. Eur. J. Cancer 49 (Suppl. 2), a2 (2013
94. Morris, J. C. et al. Correlation of interferon-γ (IFN γ) response with survival in a phase II hyperacute (HAL) immunotherapy trial for non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 30 (Suppl.), a2571 (2012
95. Morris, J. C. et al. Potential chemo-sensitization effect of tergenpumatucel L immunotherapy in treated patients with advanced non-small cell lung cancer [abstract]. J. Clin. Oncol. 31 (Suppl.), a8094 (2013
96. Macías, A. et al. Active specific immunotherapy with racotumomab in the treatment of advanced NSCLC [abstract]. Ann. Oncol. 23 (Suppl. 9), a1238PD (2012
97. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01460472 (2014
98. Dudley, M. E. et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233-5239 (2008
99. Robbins, P. F. et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183, 1185-1192 (1996
100. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00796445 (2014
101. Tarhini, A. A. et al. Safety and immunogenicity of vaccination with MART 1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF 3512676 and GM CSF in metastatic melanoma. J. Immunother. 35, 359-366 (2012
102. Odunsi, K. et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY ESO 1 antigen in ovarian cancer and melanoma patients. Proc. Natl Acad. Sci. USA 109, 5797-5802 (2012
103. Becker, J. C. et al. Survivin-specific T cell reactivity correlates with tumor response and patient survival: A phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol. Immunother. 61, 2091-2103 (2012
104. Ulloa-Montoya, F. et al. Predictive gene signature in MAGE A3 antigen-specific cancer immunotherapy. J. Clin. Oncol. 31, 2388-2395 (2013
105. Morgan, R. A. et al. Cancer regression and neurological toxicity following anti MAGE a3 TCR gene therapy. J. Immunother. 36, 133-151 (2013
106. Oshita, C. et al. Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial. Oncol. Rep. 28, 1131-1138 (2012
107. Aarntzen, E. H. et al. Targeting CD4(+) T helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res. 73, 19-29 (2013
108. Morton, D. I., Mozillo, N. & Thompson, J. F. An international, randomized phase III trial of Bacillus Calmetter Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites [abstract]. J. Clin. Oncol. 25 (Suppl.), a1078 (2001
109. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01546571 (2014
110. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01729663 (2014
111. Dillman, R. O. et al. Tumor stem cell antigens as consolidative active specific immunotherapy: A randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J. Immunother. 35, 641-649 (2012
112. Buanes, T., Maurel, J., Liauw, W., Hebbar, M. & Nemunaitis, J. A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC) [abstract]. J. Clin. Oncol. 27 (Suppl. 15), a4601 (2009
113. Middleton, G. W. et al. A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer [abstract]. J. Clin. Oncol. 31 (Suppl.), LBA4004 (2013
114. Hardacre, J. M. et al. Addition of algenpantucel L immunotherapy to standard adjuvant therapy for pancreatic cancer: A phase 2 study. J. Gastrointest. Surg. 17, 94-100 (2013
115. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01836432 (2014
116. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01072981 (2014
117. Gjertsen, M. K. et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int. J. Cancer 92, 441-450 (2001
118. Wedén, S. et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K ras. Int. J. Cancer 128, 1120-1128 (2011
119. Morse, M. A. et al. Novel adenoviral vector induces T cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol. Immunother. 62, 1293-1301 (2013
120. Hanna, M. G. Jr, Hoover, H. C. Jr, Vermorken, J. B., Harris, J. E. & Pinedo, H. M. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: First randomized phase III trials show promise. Vaccine 19, 2576-2582 (2001
121. Vermorken, J. B. et al. Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial. Lancet 353, 345-350 (1999
122. Xiang, B., Snook, A. E., Magee, M. S. & Waldman, S. A. Colorectal cancer immunotherapy. Discov. Med. 15, 301-308 (2013
123. Morse, M. A. et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM CSF for resected metastatic colorectal cancer. Ann. Surg. 258, 879-886 (2013
124. Amin, A. et al. Prolonged survival with personalized immunotherapy (AGS 003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC) [abstract]. J. Clin. Oncol. 31 (Suppl. 6), a357 (2013
125. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01582672 (2014
126. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01265901 (2014
127. Keilholz, U. et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 113, 6541-6548 (2009
128. Van Tendeloo, V. F. et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl Acad. Sci. USA 107, 13824-13829 (2010
129. Osterborg, A., Henriksson, L. & Mellstedt, H. Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma. Acta Oncol. 39, 797-800 (2000
130. Schuster, S. J. et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29, 2787-2794 (2011
131. Inogès, S. et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl Cancer Inst. 98, 1292-1301 (2006
132. Rossmann, E. et al. Randomized phase II study of BLP25 liposome vaccine (L-BLP25) in patients with multiple myeloma [abstract]. Blood 118, a2927 (2011
133. Hoos, A., Britten, C. M., Huber, C. & O'Donnell Tormey, J. A methodological framework to enhance the clinical success of cancer immunotherapy. Nat. Biotechnol. 29, 867-870 (2011
134. Choudhury, A. et al. Clinical results of vaccine therapy for cancer: Learning from history for improving the future. Adv. Cancer Res. 95, 147-202 (2006
135. Testori, A. et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C 100 21 Study Group. J. Clin. Oncol. 26, 955-962 (2008
136. Schellhammer, P. F. et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 81, 1297-1302 (2013
137. Hale, D. F. et al. Cancer vaccines: Should we be targeting patients with less aggressive disease? Expert Rev. Vaccines 11, 721-731 (2012
138. Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860-875 (2012
139. Apetoh, L. et al. Toll-like receptor 4 dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050-1059 (2007
140. Suzuki, Y. et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res. 72, 3967-3976 (2012
141. Galluzzi, L., Senovilla, L., Zitvogel, L. & Kroemer, G. The secret ally: Immunostimulation by anticancer drugs. Nat. Rev. Drug Discov. 11, 215-233 (2012
142. Xynos, I. D. et al. Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer. Oncology 84, 273-283 (2013
143. Gassner, F. J. et al. Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia. Cancer Immunol. Immunother. 60, 75-85 (2011
144. Salem, M. L. et al. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J. Immunol. 182, 2030-2040 (2009
145. Vincent, J. et al. 5 Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70, 3052-3061 (2010
146. Reers, S. et al. Cytokine changes in response to radio-/chemotherapeutic treatment in head and neck cancer. Anticancer Res. 33, 2481-2489 (2013
147. Adotevi, O. et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J. Immunother. 33, 991-998 (2010
148. Jordan, J. T. et al. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol. Immunother. 57, 123-131 (2008
149. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01675765 (2014
150. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01639885 (2014
151. Formenti, S. C. & Demaria, S. Systemic effects of local radiotherapy. Lancet Oncol. 10, 718-726 (2009
152. Finkelstein, S. E. et al. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int. J. Radiat. Oncol. Biol. Phys. 82, 924-932 (2012
153. Hurwitz, A. A., Yu, T. F., Leach, D. R. & Allison, J. P. CTLA 4 blockade synergizes with tumor-derived granulocyte-macrophage colony stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl Acad. Sci. USA 95, 10067-10071 (1998
154. Curran, M. A., Montalvo, W., Yagita, H. & Allison, J. P. PD 1 and CTLA 4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107, 4275-4280 (2010
155. Hodi, F. S. et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100, 4712-4717 (2003
156. Yuan, J. et al. CTLA 4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: Three cases. Cancer Immunol. Immunother. 60, 1137-1146 (2011
157. Scholl, S. M., Crocker, P., Tang, R., Pouillart, P. & Pollard, J. W. Is colony-stimulating factor 1 a key mediator of breast cancer invasion and metastasis? Mol. Carcinog. 7, 207-211 (1993
158. Scholl, S. M. et al. Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer. Br. J. Cancer 69, 342-346 (1994
159. Scholl, S. M. et al. Anti colony stimulating factor 1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J. Natl Cancer Inst. 86, 120-126 (1994
160. Espinosa, I. et al. CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis. Am. J. Pathol. 179, 2100-2107 (2011
161. Baron, C. et al. Modulation of MHC class II transport and lysosome distribution by macrophage-colony stimulating factor in human dendritic cells derived from monocytes. J. Cell Sci. 114, 999-1010 (2001
162. DeNardo, D. G. et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54-67 (2011
163. El-Gamal, M. I., Anbar, H. S., Yoo, K. H. & Oh, C. H. FMS Kinase Inhibitors: Current Status and Future Prospects. Med. Res. Rev. 33, 599-636 (2013
164. Burger, J. A., Stewart, D. J., Wald, O. & Peled, A. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev. Anticancer Ther. 11, 621-630 (2011
165. RAIDS project. Rational Molecular Assessment Innovative drug selection [online], http://www.raids-fp7.eu (2014)
166. Corbière, V. et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 71, 1253-1262 (2011
167. Parmiani, G., De Filippo, A., Novellino, L. & Castelli, C. Unique human tumor antigens: Immunobiology and use in clinical trials. J. Immunol. 178, 1975-1979 (2007
168. Coley, W. B. The treatment of malignant tumours by repeated inoculations of erysipelas: With a report of ten original cases. Am. J. Med. Sci. 105, 487-511 (1893
169. Burnet, F. M. & Fenner, F. The Production of Antibodies, 2nd edn (Macmillan, Melbourne, 1949
170. Klein, G., Sjogren, H. O., Klein, E. & Hellstrom, K. E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20, 1561-1572 (1960
171. Burnet, F. M. Immunological aspects of malignant disease. Lancet 1, 1171-1174 (1967
172. Steinman, R. M. & Cohn, Z. A. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 137, 1142-1162 (1973
173. Van Der Bruggen, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647 (1991
174. Ilson, D. H. et al. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. J. Clin. Oncol. 10, 1124-1130 (1992
175. McLaughlin, P. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825-2833 (1998
176. Rosenberg, S. A. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4, 321-327 (1998
177. Garrison, K. et al. The small molecule TGF-beta signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunol. Immunother. 61, 511-521 (2012
178. Ashizawa, T. et al. Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. Int. J. Oncol. 38, 1245-1252 (2011
179. Hou, D. Y. et al. Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1 methyl tryptophan correlates with antitumor responses. Cancer Res. 67, 792-801 (2007
180. Dubrot, J. et al. Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells. Cancer Immunol. Immunother. 59, 1621-1631 (2010
181. Takeda, K. et al. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. J. Immunol. 184, 5493-5501 (2010
182. Westwood, J. A. et al. Enhancing adoptive immunotherapy of cancer. Expert Opin. Biol. Ther. 10, 531-545 (2010
183. Napoletano, C. et al. Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J. Cell. Mol. Med. 14, 2748-2759 (2010
184. Wright, S. E. et al. Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients- A phase I/II study. Immunol. Invest. 38, 820-838 (2009
185. Shiao, S. L. & Coussens, L. M. The tumor-immune microenvironment and response to radiation therapy. J. Mammary Gland Biol. Neoplasia 15, 411-421 (2010
186. Lugade, A. A. et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174, 7516-7523 (2005
187. Kroemer, G. & Zitvogel, L. Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy. Oncoimmunology 1, 407-408 (2012
188. Locher, C. et al. Desirable cell death during anticancer chemotherapy. Ann. NY Acad. Sci. 1209, 99-108 (2010
189. Liu, W. M., Fowler, D. W., Smith, P. & Dalgleish, A. G. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br. J. Cancer 102, 115-123 (2010
190. Araki, K. et al. mTOR regulates memory CD8 T cell differentiation. Nature 460, 108-112 (2009
191. Hähnel, P. S. et al. Targeting AKT signaling sensitizes cancer to cellular immunotherapy. Cancer Res. 68, 3899-3906 (2008
192. Kandalaft, L. E., Tanyi, J., Chiang, C., Powell, D. & Coukos, G. Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer [abstract]. Cancer Res. 73 (Suppl. 1), LB 335 (2013
193. Duraiswamy, J., Kaluza, K. M., Freeman, G. J. & Coukos, G. Dual blockade of PD 1 and CTLA 4 combined with tumor vaccine effectively restores T cell rejection function in tumors. Cancer Res. 73, 3591-3603 (2013
194. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00089856.
195. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00133224 (2014
196. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00409188 (2014
197. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00676507 (2014
198. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00019682 (2014
199. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00358566 (2014
200. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00425360 (2014
201. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00091676 (2014